Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
19.83
-1.18 (-5.62%)
At close: Mar 3, 2026, 4:00 PM EST
20.34
+0.51 (2.57%)
After-hours: Mar 3, 2026, 7:01 PM EST
Amphastar Pharmaceuticals Revenue
In the year 2025, Amphastar Pharmaceuticals had annual revenue of $719.89M, down -1.65%. Amphastar Pharmaceuticals had revenue of $183.11M in the quarter ending December 31, 2025, a decrease of -1.83%.
Revenue (ttm)
$719.89M
Revenue Growth
-1.65%
P/S Ratio
1.25
Revenue / Employee
$364,315
Employees
1,976
Market Cap
899.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 719.89M | -12.08M | -1.65% |
| Dec 31, 2024 | 731.97M | 87.57M | 13.59% |
| Dec 31, 2023 | 644.40M | 145.41M | 29.14% |
| Dec 31, 2022 | 498.99M | 61.22M | 13.98% |
| Dec 31, 2021 | 437.77M | 87.92M | 25.13% |
| Dec 31, 2020 | 349.85M | 27.49M | 8.53% |
| Dec 31, 2019 | 322.36M | 27.69M | 9.40% |
| Dec 31, 2018 | 294.67M | 54.49M | 22.69% |
| Dec 31, 2017 | 240.18M | -14.99M | -5.87% |
| Dec 31, 2016 | 255.17M | 3.65M | 1.45% |
| Dec 31, 2015 | 251.52M | 41.06M | 19.51% |
| Dec 31, 2014 | 210.46M | -19.22M | -8.37% |
| Dec 31, 2013 | 229.68M | 25.36M | 12.41% |
| Dec 31, 2012 | 204.32M | 85.97M | 72.63% |
| Dec 31, 2011 | 118.36M | -12.38M | -9.47% |
| Dec 31, 2010 | 130.74M | 46.46M | 55.13% |
| Dec 31, 2005 | 84.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 887.40M |
| Tilray Brands | 837.32M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Alvotech | 573.35M |
| Esperion Therapeutics | 303.80M |
| Ironwood Pharmaceuticals | 296.15M |
| Harrow | 272.30M |
AMPH News
- 3 days ago - Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label - Seeking Alpha
- 5 days ago - Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 - Accesswire
- 7 days ago - Amphastar Announces FDA Approval for Ipratropium Bromide HFA - Accesswire
- 11 days ago - Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026 - Accesswire
- 6 weeks ago - Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - Accesswire
- 7 weeks ago - Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference - Accesswire